CoChat

CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease

Open access
Southon, Adam, Szostak, Kathryn, Acevedo, Karla M., Dent, Krista A., Volitakis, Irene, Belaidi, Abdel A., Barnham, Kevin J., Crouch, Peter J., Ayton, Scott, Donnelly, Paul S., Bush, Ashley I. · 2020 · British Journal of Pharmacology
Cited by 136

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Diacetyl‐bis(4‐methyl‐3‐thiosemicarbazonato)copper II(Cu II(atsm)) ameliorates neurodegeneration and delays disease progression in mouse models of amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), yet the mechanism of action remains uncertain. Promising results were recently reported for separate Phase 1 studies in ALS patients and PD patients. Affected tissue in these disorders shares features of elevated Fe, low glutathione and increased lipid peroxidation consistent with ferroptosis, a novel form of regulated cell death. We therefore evaluated the ability of Cu II(atsm) to inhibit ferroptosis. Experimental Approach: Ferroptosis was induced in neuronal cell models by inhibition of glutathione peroxidase‐4 activity with RSL3 or by blocking cystine uptake with erastin. Cell viability and lipid peroxidation were assessed and the efficacy of Cu II(atsm) was compared to the known antiferroptotic compound liproxstatin‐1. Key Results: Cu II(atsm) protected against lipid peroxidation and ferroptotic lethality in primary and immortalised neuronal cell models (EC 50: ≈130 nM, within an order of magnitude of liproxstatin‐1). Ni II(atsm) also prevented ferroptosis with similar potency, whereas ionic Cu II did not. In cell‐free systems, Cu II(atsm) and Ni II(atsm) inhibited Fe II‐induced lipid peroxidation, consistent with these compounds quenching lipid radicals. Conclusions and Implications: The antiferroptotic activity of Cu II(atsm) could therefore be the disease‐modifying mechanism being tested in ALS and PD trials. With potency in vitro approaching that of liproxstatin‐1, Cu II(atsm) possesses favourable properties such as oral bioavailability and entry into the brain that make it an attractive investigational product for clinical trials of ferroptosis‐related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14881

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Southon, A., Szostak, K., Acevedo, K. M., Dent, K. A., Volitakis, I., Belaidi, A. A., Barnham, K. J., Crouch, P. J., Ayton, S., Donnelly, P. S., & Bush, A. I.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2020-01-14
Volume
177
Issue
3
Pages
656-667
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2981700910
Cited by
136
References
8
FWCI
9.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.